中望軟件(688083.SH):擬1.65億元收購北京博超64.66%股權
格隆匯4月27日丨中望軟件(688083.SH)公佈,公司("受讓方")分別與廣州拓歐信息技術有限公司(以下簡稱"廣州拓歐")、林飛、肖舟(以下統稱"轉讓方")簽署《股權轉讓協議》,擬使用自有資金16,482.6261萬元人民幣收購北京博超合計64.6626%的股權。
同時,公司與本次收購後北京博超其他股東、北京博超簽署《股東協議書》,公司有權根據北京博超的經營狀況,在2024-2026年分批次自主選擇收購北京博超剩餘35.3374%股權,使目標公司最終成為中望軟件的全資子公司。
本次交易完成後,北京博超將成為公司的控股子公司,納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.